Dr. Jeffery Shyh-Jye Lin, MD

Dr. Lin practices at West Los Angeles Medical Center in Los Angeles, California, part of Kaiser Permanente.

Dr. Lin's NPI, 1598296709, was assigned on March 21, 2017. Dr. Lin graduated from Baylor College Of Medicine in 2017. Dr. Lin holds Washington license MD61272633.

Dr. Lin's primary practice is West Los Angeles Medical Center, at 6041 Cadillac Ave, Los Angeles, CA 90034 in Los Angeles County. The practice phone is (213) 857-2201.

Dr. Lin's primary practice is West Los Angeles Medical Center in Los Angeles, California, part of Kaiser Permanente. Dr. Lin is also affiliated with Keck Hospital of USC. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Dr. Lin to 1 more hospital, 2 medical groups, 1 dialysis center and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 5 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Lin's licenses on file in 3 states: Washington, California and New York.

Dmand AI lists enlarged prostate, erectile dysfunction, kidney removal surgery and urinary endoscopy among the conditions Dr. Lin treats.

CMS data shows 95 Medicare services from Dr. Lin across 3 procedure codes in 2024, for 83 Medicare patients. Medicare paid $6,145 for them. Every service was in an office.

CMS counts 83 Medicare patients who saw Dr. Lin in 2024. The largest group is 75 to 84, with 36 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 64, with 30% women.

In 2024, Dr. Lin wrote 109 Medicare Part D claims for 60 patients. 89% of them were for generic drugs. CMS names the drug for 16 of them, across 1 drug with 11 or more claims each, at $196 in total drug cost. In 2023, CMS named 91 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Lin for performance year 2024, reported as part of a group. Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lin as offering telehealth.

Dmand AI links 6 papers to Dr. Lin, published from 2023 to 2025. 2024 was the busiest year, with 2. The most frequent topics are Ureter, Robotic Surgical Procedures and Postoperative Complications. Dr. Lin has published most often in Urology. Dr. Lin's most frequent co-authors are Lee Cheng Zhao, MD, Daniel D. Eun, MD and Michael Stifelman, MD.

CMS Open Payments shows 72 general payments to Dr. Lin from 12 drug and device companies from 2019 to 2025. Food and beverage make up the largest share, 72% of the total. Boston Scientific Corporation paid the most, $3,122.

Dr. Lin graduated from Baylor College Of Medicine in 2017.

Dr. Lin is in network with 7 carriers, including Aetna, Kaiser Permanente and Cigna. EPO plans come from the most carriers, 3. Check the plan with the practice before a visit.